Decision: Favourable

Decisions Table

Study Title:

A Phase 3, open-label, parallel group, multicenter, extension study evaluating the long-term treatment of bimekizumab in study participants with moderate to severe hidradenitis suppurativa

  • NREC Code:

    22-NREC-CT-071

  • Decision:

    Favourable

  • Meeting Date:

    09/03/2022

  • Study Type:

    CT application

  • Principal Investigator:

    Professor Brian Kirby

  • PI Institution:

    St Vincent's University Hospital

  • Sponsor:

    Parexel International

Scroll to Top